Daxor Corporation heads into the close of April with a telling insider signal — and a sharp one-day reversal — driving the narrative.
The most interesting data point this week isn't the short book. It's the C-suite buying pattern. Both the President/CEO Michael Feldschuh and CFO Robert Michel made open-market purchases in late March and early April at prices between $9.07 and $9.90, adding 2,000 shares combined for a net consideration of roughly $19,000. These are modest dollar amounts for a company with a $67 million market cap, but the pattern is consistent — Feldschuh has now bought in the open market three times since March 2025, paying between $7.72 and $9.07 per share. The current price of $10.65 is materially above every one of those purchase prices.
That insider confidence has been paired with a quiet commercial push. On April 8, Daxor announced a new Blood Volume Analysis program at a high-volume Ohio cardiology centre, adding to its customer footprint. Then on April 28, the company was at the MedAxiom CV Transforum conference, using the forum to accelerate commercial adoption of its BVA technology. For a micro-cap medical device company still in growth mode, the combination of management buying and visible commercial traction is the main story.
The short positioning is almost entirely irrelevant here. Short interest is a fractional 0.06% of the free float — around 3,225 shares. That figure has actually declined about 11% over the past month, drifting lower in two steps. Availability is exceptionally loose at nearly 4,877% of short interest, meaning the lending pool is essentially untouched. Cost to borrow has eased to 7.0%, down from a recent high above 8.3% in mid-April. The borrow market tells a story of near-zero bearish conviction.
There is one data point worth noting on the ownership side: the Estate of Joseph Feldschuh controls roughly 43.8% of shares, making this a closely-held company where family-related entities dominate the register. Michael Feldschuh sits at 3.7%, with Jonathan Feldschuh at another 0.9%. Vanguard has a small passive slice of 0.8%, and Renaissance Technologies holds a position of around 0.5% — the only signal of quant interest. The float is thin, which amplifies the effect of even small volume swings on the share price, consistent with Wednesday's 7.7% one-day drop landing against the grain of a 5.4% gain for the full week.
The ORTEX short score of 30 ranks in the 72nd percentile of the universe — elevated relative to a stock with almost no short interest, reflecting instead the days-to-cover (DTC) rank of 74 and the utilization rank of 67. These scores reflect the thinness of the float more than any aggressive bearish positioning.
Earnings reactions have been muted in prior quarters. The last two prints each saw a 1-day decline of roughly 4.8% and 4.8% respectively, with modest five-day follow-through. No next earnings date is confirmed. With no analyst actions since a minor target-raise at Ascendiant Capital in March 2025 — well outside any meaningful recency window — the sole coverage remains a Buy at a $25 target, against a current price that still represents a substantial discount.
What to watch: whether the commercial momentum signalled at MedAxiom translates into the next quarterly update, and whether the CEO's accumulated open-market buying at sub-$10 levels sets a reference point the market begins to price in more deliberately.
See the live data behind this article on ORTEX.
Open DXR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
